Eva Simkova

Dubai, DU, United Arab Emirates

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Isolated Kidney Transplant in Primary Hyperoxaluria-1 Enabled by Small Interfering RNA (siRNA) Therapy. Is It Time for Change? Case Report and Review of the Literature.

Isolated Kidney Transplant in Primary Hyperoxaluria-1 Enabled by Small Interfering RNA (siRNA) Therapy. Is It Time for Change? Case Report and Review of the Literature.

Journal: Pediatric transplantation

Published: September 11, 2025

Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial.

Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial.

Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation

Published: March 26, 2024

Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial.

Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial.

Journal: Kidney international reports

Published: December 11, 2023

Relapsing and refractory peritoneal dialysis peritonitis caused by Corynebacterium amycolatum.

Relapsing and refractory peritoneal dialysis peritonitis caused by Corynebacterium amycolatum.

Journal: Pediatric nephrology (Berlin, Germany)

Published: September 16, 2022

Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.

Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.

Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation

Published: January 12, 2022

Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1.

Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1.

Journal: Kidney international reports

Published: November 12, 2021

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.

Journal: The New England journal of medicine

Published: March 31, 2021

Case Report: CMV-Associated Congenital Nephrotic Syndrome.

Case Report: CMV-Associated Congenital Nephrotic Syndrome.

Journal: Frontiers in pediatrics

Published: July 04, 2020

The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase ε.

The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase ε.

Journal: Journal of the American Society of Nephrology : JASN

Published: January 11, 2017

Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children.

Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children.

Journal: Journal of the American Society of Nephrology : JASN

Published: October 23, 2016

Genotype-phenotype associations in WT1 glomerulopathy.

Genotype-phenotype associations in WT1 glomerulopathy.

Journal: Kidney international

Published: August 03, 2013

Management of anemia in children receiving chronic peritoneal dialysis.

Management of anemia in children receiving chronic peritoneal dialysis.

Journal: Journal of the American Society of Nephrology : JASN

Published: March 09, 2013

Showing 1-12 of 15

Last Updated: 09/26/2026